One-third of global healthcare costs are spent on strokes. Rapid and accurate treatment
is crucial—every minute counts. StrokePointer™ enables ambulance professionals to
immediately recognize a severe stroke, such as an LVO (large vessel occlusion), and
transport patients directly to a specialized treatment center. This improves patient
outcomes and contributes to more eSicient care.
TrianecT was founded in 2022 as a spin-off from Amsterdam UMC and Neuromotion
Ventures. With this investment, the company can take the final steps toward launching
StrokePointer™ in the Netherlands and other European countries.
The investment round was led by XO Ventures, an early-stage, hands-on health/tech
investor and part of XO Capital, a single-family oSice. The firm focuses on companies
that provide solutions to enhance quality of life.
“This innovation fits perfectly with our mission to make healthcare more eSicient and
patient-centered,” says Karel Stolper, board member of CbusineZ. “StrokePointer™
enables faster triage, in the right place and at the right time.”
CEO and co-founder Wouter Potters adds: “Thanks to this investment—and the strategic
involvement of our new partners—we can accelerate the translation of our technology
from scientific breakthrough to real-world application. This will ensure every stroke
patient receives faster and better care.”
With this investment, TrianecT is fully focused on the European market launch of
StrokePointer™, aiming to structurally improve pre-hospital stroke care.